YZYing Zhang

Ying Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ying Zhang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Jianjing Yang

    Department of Neurosurgery, The first affiliated hospital of Wenzhou Medical University, Wenzhou, China

    3 shared publications
  • Hao Wang

    Department of Neurosurgery, The first affiliated hospital of Wenzhou Medical University, Wenzhou, China

    2 shared publications
  • Peiqi Zhao

    Department of Neurosurgery, The first affiliated hospital of Wenzhou Medical University, Wenzhou, China

    2 shared publications
  • Qichuan Zhuge

    Department of Neurosurgery, The first affiliated hospital of Wenzhou Medical University, Wenzhou, China

    2 shared publications
  • Fan Tang

    Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Zhejiang-US Joint Laboratory for Aging and Neurological Disease Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    1 shared publication
  • Fan Tang

    Department of Neurosurgery, The first affiliated hospital of Wenzhou Medical University, Wenzhou, China

    1 shared publication

Latest Publications

  • Ginsenoside compound K targets DUSP5 to inhibit the malignant progression of glioblastoma via the ERK pathway

    by Fan Tang, Hong Chen, Shunda Wang, Jingyue Pang, Shengkai He, Xijun Chen, Yu Zhang, Jianjing Yang, Ying Zhang


  • HRH1-targeting mAb: a precision therapeutic strategy for Glioblastoma

    by Kankai Wang, Peiqi Zhao, Xiaohong Zhu, Fan Tang, Hong Chen, Ying Zhang, Hao Wang, Yu Chen, Yuanbo Pan, Qichuan Zhuge, et al.

    Glioblastoma multiforme (GBM) remains one of the most aggressive primary brain tumors with limited therapeutic options. The efficacy of standard temozolomide chemotherapy is critically influenced by O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. While monoclonal antibody (mAb)-based biologics represent a promising therapeutic approach, current clinical trials have failed to demonstrate significant improvement in overall patient survival. In this study, systematic screening identified histamine H1 receptor (HRH1) as a potential therapeutic target. Genetic silencing of HRH1 significantly inhibited GBM cell proliferation, migration, and invasion both in vitro and in vivo. Pharmacological validation using the HRH1-specific antagonist terfenadine confirmed the anti-tumor effects of HRH1 targeting. Based on these findings, we developed an HRH1-targeting mAb that demonstrated potent anti-tumor activity in GBM xenograft models. Mechanistic investigations revealed that the therapeutic effect was mediated through protein kinase C (PKC)-dependent regulation of the RAF/MEK/ERK signaling pathway. In conclusion, we provided a new target, HRH1, for treating GBM and constructed an effective therapeutic mAb.


  • Open Access

    NeuroD4 converts glioblastoma cells into neuron-like cells through the SLC7A11-GSH-GPX4 antioxidant axis

    by Hao Wang, Peiqi Zhao, Ying Zhang, Zhen Chen, Han Bao, Wenqi Qian, Jian Wu, Zhenqiu Xing, Xiaowei Hu, Kunlin Jin, et al.

    Cell fate and proliferation ability can be transformed through reprogramming technology. Reprogramming glioblastoma cells into neuron-like cells holds great promise for glioblastoma treatment, as it induces their terminal differentiation. NeuroD4 (Neuronal Differentiation 4) is a crucial transcription factor in neuronal development and has the potential to convert astrocytes into functional neurons. In this study, we exclusively employed NeuroD4 to reprogram glioblastoma cells into neuron-like cells. In vivo, the reprogrammed glioblastoma cells demonstrated terminal differentiation, inhibited proliferation, and exited the cell cycle. Additionally, NeuroD4 virus-infected xenografts exhibited smaller sizes compared to the GFP group, and tumor-bearing mice in the GFP+NeuroD4 group experienced prolonged survival. Mechanistically, NeuroD4 overexpression significantly reduced the expression of SLC7A11 and Glutathione peroxidase 4 (GPX4). The ferroptosis inhibitor ferrostatin-1 effectively blocked the NeuroD4-mediated process of neuron reprogramming in glioblastoma. To summarize, our study demonstrates that NeuroD4 overexpression can reprogram glioblastoma cells into neuron-like cells through the SLC7A11-GSH-GPX4 signaling pathway, thus offering a potential novel therapeutic approach for glioblastoma.